 Obalon Therapeutics, Inc. OBLN, a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that its gas-filled balloon is not the subject of the April 27, 2020 letter issued by the FDA to health care providers warning of serious potential risks, including deaths, associated with the use of liquid-filled intragastric balloons. The Obalon swallowable, gas-filled balloon system utilizes a very different design and technology than the liquid-filled balloons cited now in four FDA letters to health care providers. 